Literature DB >> 3876270

Serum IL-2 inhibitor in mice. II. Molecular characteristics.

D Male, R Lelchuk, S Curry, G Pryce, J H Playfair.   

Abstract

The molecular characteristics of a serum IL-2 inhibitor were determined by fractionating active sera from normal and malaria-infected mice, and assaying inhibitory activity in blocking production and expression of IL-2 activity. Using isoelectric focusing and ion exchange chromatography, the activity resolved in a single peak (pI = 6.2). HPLC gel filtration resolved two peaks of activity (50,000 and 25,000 MW) which are probably related. The molecule is precipitated by 50% saturated ammonium sulphate, and is destroyed by heating above 56 degrees or by acidification below pH 4.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3876270      PMCID: PMC1453661     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  13 in total

1.  Immune response suppression by an inhibitor in normal and immune mouse serum.

Authors:  B C Veit; J G Michael
Journal:  Nat New Biol       Date:  1972-02-23

2.  Effect of normal mouse serum on mouse lymphocyte transformation in vitro.

Authors:  D S Nelson; C N Shneider
Journal:  Eur J Immunol       Date:  1974-02       Impact factor: 5.532

3.  Characterization of an immunosuppressive factor present in mouse serum.

Authors:  B Veit; J G Michael
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

4.  Effect of an immunosuppressive serum alpha-2-glycoprotein with ribonuclease activity on the proliferation of human lymphocytes in culture.

Authors:  J D Milton
Journal:  Immunology       Date:  1971-02       Impact factor: 7.397

5.  Nonspecific inhibitor released by T acceptor cells reduces the production of interleukin-2.

Authors:  M Malkovsky; G L Asherson; B Stockinger; M C Watkins
Journal:  Nature       Date:  1982-12-16       Impact factor: 49.962

6.  Suppression of B-cell and T-cell responses by the prostaglandin-induced T-cell-derived suppressor (PITS). I. Analysis of the PITS beta factor.

Authors:  T J Rogers; L Campbell; K Calhoun; I Nowowiejski; D R Webb
Journal:  Cell Immunol       Date:  1982-01-15       Impact factor: 4.868

7.  A selective inhibitor of cell proliferation from normal serum.

Authors:  W N Harrington; G C Godman
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

8.  Normal mouse serum immunosuppressive activity: action on adherent cells.

Authors:  R S Martineau; J S Johnson
Journal:  J Immunol       Date:  1978-05       Impact factor: 5.422

9.  The production of proliferation inhibitory factor (pif) by mouse spleen cells in vitro.

Authors:  A M Badger; S R Cooperband; V J Merluzzi
Journal:  J Immunol       Date:  1974-04       Impact factor: 5.422

10.  Lyt-23+ cyclophosphamide-sensitive T cells regulate the activity of an interleukin 2 inhibitor in vivo.

Authors:  C Hardt; M Röllinghoff; K Pfizenmaier; H Mosmann; H Wagner
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

View more
  8 in total

1.  Helper and suppressor activities of an autoreactive mouse thyroglobulin-specific T-cell clone.

Authors:  B R Champion; P Hutchings; S Davies; S Marshall-Clarke; A Cooke; I M Roitt
Journal:  Immunology       Date:  1986-05       Impact factor: 7.397

Review 2.  Interactions of viruses with the immune system.

Authors:  C A Mims
Journal:  Clin Exp Immunol       Date:  1986-10       Impact factor: 4.330

3.  Immunotherapy of collagen-induced arthritis by a T-cell antiproliferative molecule.

Authors:  D J Spannaus-Martin; R Holmdahl; T F Kresina
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

4.  Interleukin 2 inhibitor in synovial fluid.

Authors:  P Emery; K C Gentry; A Kelso; I R Mackay
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

5.  Serum IL-2 inhibitor in mice. I. Increase during infection.

Authors:  R Lelchuk; J H Playfair
Journal:  Immunology       Date:  1985-09       Impact factor: 7.397

6.  Decreased interleukin 2 inhibitor in sera of patients with autoimmune disorders.

Authors:  J Y Djeu; T Kasahara; J E Balow; G C Tsokos
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

7.  Interleukin-2-dependent control of disease development in spontaneously diabetic BB rats.

Authors:  J Zielasek; V Burkart; P Naylor; A Goldstein; U Kiesel; H Kolb
Journal:  Immunology       Date:  1990-02       Impact factor: 7.397

8.  Decreased activity of interleukin-2 inhibitor in plasma of patients with systemic lupus erythematosus.

Authors:  E J Kucharz; S Sierakowski; J S Goodwin
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.